This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.
⚠ Important:* Compounded semaglutide and tirzepatide are not FDA-approved medications. They are manufactured outside the regulatory framework that governs brand-name drugs. Information here is educational only — not a recommendation. Do not source medications from unverified suppliers.
The GLP-1 medication shortage that emerged from 2022 to 2024 created an unusual situation: the FDA, under its shortage exemption authority, permitted compounding pharmacies to manufacture copies of semaglutide and tirzepatide. An entire market — from small compounding pharmacies to large telehealth platforms — grew rapidly to meet demand.
By mid-2024, platforms like Hims & Hers, Ro, Mochi Health, and hundreds of individual compounders were offering compounded semaglutide and tirzepatide at a fraction of the branded price. For the uninsured and underinsured, compounded GLP-1s became a genuine access pathway.
Then the regulatory ground shifted. The FDA began removing these medications from the shortage list as branded supply recovered — triggering legal battles, provider confusion, and patient uncertainty that continued into 2026.
This article explains the current state of compounded GLP-1s: what they are, what the FDA says, what the safety differences are, what they cost, and how to evaluate whether they're a reasonable option for you.
What Is a Compounded Medication?
Drug compounding is the practice of preparing a customized medication for an individual patient, typically when: - A commercially available drug is unavailable (shortage) - A patient needs a dosage or formulation not commercially available - A patient has an allergy to an ingredient in the commercial product
Compounding is regulated under the Federal Food, Drug, and Cosmetic Act and overseen by the FDA for larger compounders (503B facilities) and state boards of pharmacy for smaller ones (503A pharmacies).
Critically: Compounded drugs are not FDA-approved. They do not go through the FDA's pre-market review process for safety, efficacy, or manufacturing quality. FDA approval requires extensive clinical trials, manufacturing inspections, and post-market surveillance requirements that compounders are not subject to.
The Shortage Exemption: How Compounded GLP-1s Became Legal
Under Section 503A and 503B of the FD&C Act, compounders may legally prepare copies of commercially available drugs when those drugs appear on the FDA's drug shortage list. This is the exemption that opened the door for compounded semaglutide and tirzepatide.
The timeline: - 2022–2024: Ozempic, Wegovy, Mounjaro, and Zepbound were all on the FDA shortage list at various points due to manufacturing constraints and explosive demand - 503B compounders (larger facilities that can sell to pharmacies and prescribers without patient-specific prescriptions) began producing compounded semaglutide and tirzepatide at scale - 503A pharmacies (patient-specific prescriptions) also proliferated, often operating through telehealth platforms - March 2024: The FDA proposed removing semaglutide from the shortage list, triggering lawsuits from compounding industry groups seeking to block the decision - Early 2025: The FDA formally removed tirzepatide from the shortage list, declaring adequate commercial supply - 2025–2026: Legal challenges from 503B compounders resulted in injunctions and counter-injunctions; as of May 2026, the situation remains in active legal flux
Practical implication: Whether compounded GLP-1s are legally available to you in May 2026 depends on the current status of litigation and your state's pharmacy regulations. Check fda.gov/drugs/drug-safety-and-availability/drug-shortages for the current shortage designation and consult your provider.
What's in Compounded Semaglutide?
This is where patients often don't realize there's a key distinction.
Branded Wegovy/Ozempic contains semaglutide as the active ingredient, formulated as a sodium salt for injection stability.
Most compounded semaglutide contains semaglutide sodium or semaglutide acetate — slightly different salt forms of the same molecule. The FDA's position is that these salt forms are not identical to the branded product and that compounders cannot legally claim to be producing the same drug. Novo Nordisk has taken the position that only their formulation has the safety and efficacy data from clinical trials.
503A compounders sometimes add: - Vitamin B12 (cyanocobalamin or methylcobalamin) — claimed to reduce nausea, though not supported by clinical evidence specific to GLP-1 medications - L-carnitine — a supplement sometimes added by compounders without specific evidence of synergistic benefit - Additional excipients that differ from the FDA-approved formulation
The addition of these ingredients creates formulations that are further removed from the clinical trial-tested product.
Safety Concerns: What the FDA Has Said
The FDA has issued multiple public communications about compounded GLP-1 medications:
In October 2023, the FDA issued a safety alert documenting reports of serious adverse events — including hospitalization — associated with compounded semaglutide, primarily related to dosing errors. Specifically:
- Unit confusion: Compounded semaglutide is often dosed in mg but drawn up in units (like insulin) using insulin syringes. Errors of 10-fold overdose were reported by patients who misread the concentration.
- Variable concentrations: Different compounders use different concentrations (e.g., 5 mg/mL vs. 2.5 mg/mL). A patient switching compounders or pharmacies could inadvertently take double or half their intended dose.
- Manufacturing quality variability: Unlike 503B facilities, which the FDA periodically inspects, many 503A pharmacies operate under state-level oversight of variable rigor.
This does not mean all compounded GLP-1s are dangerous — many patients have used them safely. It does mean the quality control and patient education standards are less consistent than with the branded auto-injector pens, which use fixed doses and cannot be accidentally overdosed.
The Telehealth Platform Landscape
Several direct-to-consumer telehealth companies built substantial businesses around compounded GLP-1s during the shortage period. As of May 2026, their status has evolved:
| Platform | Current Status (May 2026) | Notes |
|---|---|---|
| Hims & Hers | Scaled back compounded GLP-1 offerings post-shortage resolution; pivot to branded products | Was one of largest compounders by volume |
| Ro (Roman) | Offering branded prescriptions through insurance + self-pay; compounded products legally uncertain | |
| Mochi Health | Medically supervised platform; offering both branded and compounded where legal | Emphasizes clinical oversight |
| LifeMD | Insurance-focused; fewer compounded offerings | |
| Calibrate | Program-based; primarily branded medications | Emphasizes behavioral component |
The landscape is shifting rapidly. Before using any telehealth platform for compounded GLP-1s, confirm: 1. The platform employs US-licensed prescribers who conduct genuine medical evaluations 2. The compounding pharmacy holds 503A or 503B accreditation from a recognized body (PCAB accreditation from the Pharmacy Compounding Accreditation Board is the gold standard) 3. The medication is listed with a specific lot number and concentration 4. The platform provides clear dosing instructions in mg, not units
Cost Comparison: Compounded vs. Branded in 2026
| Option | Approx. Monthly Cost |
|---|---|
| Branded Wegovy (with savings card, commercially insured) | $0–$25 |
| Branded Zepbound via LillyDirect self-pay | $349–$549 |
| Compounded semaglutide (503A, telehealth) | $150–$350 |
| Compounded tirzepatide (503A, telehealth) | $200–$450 |
| Branded Wegovy without insurance (list price) | ~$1,349 |
The cost advantage of compounded products is most meaningful for uninsured patients without access to LillyDirect and without eligibility for manufacturer savings cards (i.e., Medicare beneficiaries, Medicaid patients, or those whose insurer doesn't cover GLP-1 medications and who don't meet Lilly self-pay criteria).
Use our cost estimator to model your specific insurance and income scenario and compare options side-by-side.
Who Should Consider Compounded GLP-1s?
Given the regulatory complexity, compounded GLP-1s occupy a specific niche. They may be reasonable to consider if:
- You have no insurance coverage and the LillyDirect pricing is still out of reach
- Branded products are genuinely unavailable (shortage conditions)
- You are working with a physician or NP who will actively supervise your dosing and labs
- You have verified the compounding pharmacy's 503B or PCAB accreditation
- You understand the dosing instructions precisely and use the correct syringe/device
They are not appropriate if: - You can access branded medications at affordable cost through savings programs - You are self-prescribing or using an online service that does not involve a real clinical evaluation - You are obtaining medications from international pharmacies, grey-market websites, or any seller that does not require a US prescription - You have not verified the current legal status of compounded GLP-1s in your state
Red Flags: Signs of an Unsafe Source
Do not source medications from unverified suppliers.
Immediate red flags: - No prescription required - No prescriber listed, or prescriber "auto-approves" with a brief online questionnaire and no follow-up - Medication offered as "research compound" or "for research use only" - No labeled lot number, expiration date, or concentration on the vial - Dramatically lower prices than even legitimate compounders ($50–$80/month for semaglutide should raise concerns) - Claims of "pharmaceutical-grade" semaglutide from overseas suppliers
The FDA has issued warnings about the importation and sale of unapproved drugs online. These can contain wrong ingredients, contaminated substances, or zero active pharmaceutical ingredient.
Independent Analysis: What the Compounded GLP-1 Market Actually Looks Like in 2026
Three observations from FDA enforcement actions, state board records, and independent product testing that change how to evaluate compounded GLP-1 options in 2026:
1. The legal framework is narrower than most marketing suggests
Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding for individual patients with a valid prescription, but only when an FDA-approved alternative is unavailable due to shortage or a specific clinical reason (e.g., allergy to an inactive ingredient). The shortage exception is the entire basis for most compounded semaglutide and tirzepatide currently being sold. When the FDA removed semaglutide from the shortage list in February 2025 and gave 503A pharmacies until late May 2025 to wind down, most compounders complied. Some did not. Marketing that says "FDA-approved compounded semaglutide" is misleading — compounded drugs are never FDA-approved, only the underlying molecule is.
2. The supply chain has three very different quality tiers
Independent testing published by FDA and academic labs has identified three distinct product tiers being sold under the "compounded GLP-1" umbrella: (1) Legitimate 503B-licensed compounded drugs with documented sourcing and chromatography-verified purity — these are clinically reasonable when legally available; (2) 503A small-pharmacy compounded drugs with variable quality control — purity has tested between 80% and 100% in published assays, dosing accuracy varies; (3) Research-grade peptides repackaged as compounded medication — sold through online vendors with no pharmacy license, sometimes shipped from outside the U.S., often labeled "for research use only" but marketed for human use. The third tier is illegal and frequently dangerous.
3. The cost gap is narrowing
The original economic argument for compounded GLP-1 was cost: $250–400/month compared to $1,000+ for branded Wegovy or Zepbound. With Eli Lilly's Zepbound vial program (introduced 2024) offering single-dose vials at ~$400/month for self-pay patients, and Novo Nordisk's patient assistance programs expanding, the price gap for legal branded products has narrowed substantially. For many patients, the math now favors branded medication with documented safety over compounded options of uncertain quality. The cost case for compounded versions is strongest when insurance does not cover branded medication and the patient cannot access manufacturer programs.
How to evaluate a compounded GLP-1 source if you choose this path
Verify all of: (1) the prescriber is licensed in your state and conducted a real consultation, not just a checkbox form; (2) the compounding pharmacy holds a current 503B license — verify on the FDA registered outsourcing facility list; (3) third-party purity testing certificates are available for your batch; (4) the product is sold as a finished, sterile, ready-to-inject medication, not as a powder requiring reconstitution at home; (5) the price is consistent with legitimate compounding costs — pricing dramatically below market typically indicates research-grade sourcing.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Only under specific circumstances. After the FDA removed semaglutide from the shortage list in 2025, the standard shortage-based compounding pathway closed. Compounding remains legal for specific documented clinical needs (e.g., true allergy to a branded inactive ingredient) under 503A regulations, but the bulk market has shrunk significantly. Verify the FDA Drug Shortage List for current tirzepatide and semaglutide status before purchasing.
Is compounded GLP-1 as effective as Wegovy or Zepbound?
Theoretically yes, if the active ingredient is correctly synthesized and dosed. There is no published clinical trial of compounded versions directly. Independent assays of compounded products have found purity ranging from 80% to 100% and dosing accuracy varying by ±30% in some batches. Quality varies by compounder.
What is the difference between 503A and 503B compounding pharmacies?
503A pharmacies compound for individual patients with prescriptions. They are state-licensed and have lower regulatory requirements. 503B 'outsourcing facilities' are FDA-registered and must follow Current Good Manufacturing Practice (cGMP) standards, with batch testing and FDA inspection. 503B is the higher-quality tier.
Why is compounded GLP-1 so much cheaper than Wegovy?
Compounded drugs do not have the R&D cost recovery, marketing, or brand premium of patented branded medication. With Eli Lilly's Zepbound vial program now at ~$400/month for self-pay, the gap has narrowed for legal branded options. Pricing below $200/month is typically a red flag for research-grade sourcing.
Can I buy compounded GLP-1 from overseas?
Importing prescription medication for personal use from outside the U.S. is generally not permitted under FDA personal importation policy, except for a narrow set of conditions that does not include compounded GLP-1. Products shipped from China, India, or other non-U.S. sources are typically research-grade peptides, not pharmacy-compounded medications, and are illegal to import.
What are the side effects of compounded vs. branded GLP-1?
The expected side effect profile is the same as branded medication when the active ingredient is correctly compounded. Additional risks unique to compounded products: injection-site reactions from impurity, lot-to-lot inconsistency producing inconsistent dose response, and contamination-related infections (rare, but documented in FDA enforcement actions).
Should I switch from compounded to branded GLP-1?
If you can access branded medication through insurance or manufacturer assistance, most clinicians recommend the switch — documented dosing accuracy, established safety database, and pharmacovigilance reporting all favor branded. Practical considerations include cost gap, current dose, and how long you have been on compounded therapy. Discuss with your prescriber.
Sources
- FDA. "Drug Shortages: Current and Resolved." https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
- FDA. "FDA Alerts Patients and Health Care Professionals to Dosing Errors Associated with Compounded Injectable Semaglutide." October 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-dosing-errors-associated-compounded-injectable
- FDA. "Human Drug Compounding: Laws and Policies." https://www.fda.gov/drugs/guidance-compliance-regulatory-information/compounding
- FDA Consumer Update. "Medications Purchased Online: Do You Know What You're Getting?" https://www.fda.gov/consumers/consumer-updates/medications-purchased-online-do-you-know-what-youre-getting
- Pharmacy Compounding Accreditation Board. "PCAB Accreditation Standards." https://www.pcab.org
- Novo Nordisk. "Wegovy (semaglutide) Prescribing Information." https://www.novo-pi.com/wegovy.pdf
- Eli Lilly. "LillyDirect Zepbound Self-Pay." https://www.zepbound.lilly.com/savings